Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

Total production -- Reached a quarterly record of approximately 1.62 million BOEs per day, reflecting a 19% increase, or ...

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Disposition Activity -- Q3 proceeds totaled $19.3 million, with $4.6 million in gains; year-to-date sales reached $133.8 ...

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

Exclusive Supply Agreement: A contractual arrangement where UFP Technologies ( UFPT 2.21%) is the sole supplier of specified ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.